Epidermal growth factor receptor, vascular endothelial growth factor, mouse double minute 2 homolog, Ki 67, and p53 expression in glioblastoma: A survival analysis including the prognostic value of clinical, histopathological, and immunohistochemical para
Keywords:
Clinical, glioblastoma, histopathology, immunohistochemistry, survivalAbstract
Objective: The objective of the study was to describe the clinical, histopathological, and immunohistochemical
profile of glioblastoma in patients and to correlate these findings with patient survival.
Materials and Methods: Thirty cases of histopathologically diagnosed glioblastomas were included in
this study. These cases were analyzed in detail for certain clinical and histopathological parameters.
Immunohistochemical staining for p53, epidermal growth factor receptor, vascular endothelial growth
factor, mouse double minute 2 homolog (MDM2), and Ki67 was done, and scores were calculated. Results
of these findings were correlated with patient survival.
Results: A retrospective analysis of the histopathology records and clinical case files was done in thirty cases of
glioblastoma (World Health Organization Grade IV). The mean age of presentation was 50.6 years with a male
predilection. The most common involved site was the frontal lobe. Among the clinical parameters, age of the
patient and extent of surgical resection showed a significant correlation with the patient survival. Histopathological
parameters showed no significant correlation with the patient survival, while among the immunohistochemical
parameters, expression of MDM2 showed a significant correlation with the patient survival.
Conclusion: In this study incorporating clinical, histopathological, and basic panel of immunohistochemistry,
age of the patient, extent of the surgical resection, and expression of MDM2 showed a significant correlation
with the patient survival.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.